848-849 / 2351
Key points NPC
‐
•
The current treatment recommendation is
–
radiotherapy alone for early stage
–
concurrent chemoradiotherapy (cisplatin‐based)
for locally advanced stages (III–IVB, bulky IIb)
•
IMRT is recommended for target coverage and
normal tissue sparing (xerostomia etc)
,
•
Beware of the many critical normal tissues at risk!
•
Loco‐regional control in excess of 90% at 2–4 years
with IMRT and concurrent chemotherapy
•
5‐year overall survival of ~70%